Today: 20 June 2026
Browse Category

Financial Forecasts 20 December 2025 - 21 December 2025

PepsiCo Stock (NASDAQ: PEP) News & Forecasts (Dec. 20, 2025): Elliott-Backed Cost Cuts, Walmart Lawsuit Overhang, and What Analysts Expect for 2026

PepsiCo Stock (NASDAQ: PEP) News & Forecasts (Dec. 20, 2025): Elliott-Backed Cost Cuts, Walmart Lawsuit Overhang, and What Analysts Expect for 2026

PepsiCo shares closed near $148 on Friday, down about 2.6% for 2025, as the company announced a major 2026 cost-cutting and portfolio reset influenced by Elliott Investment Management. PepsiCo plans to cut nearly 20% of U.S. SKUs and launch new products like Doritos Protein. A new lawsuit accuses PepsiCo and Walmart of price-fixing. Wall Street is adjusting price targets as these developments unfold.
21 December 2025
··
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer shares traded near $25.19 as of Dec. 20, 2025, following the company’s 2026 guidance projecting $59.5–$62.5 billion in revenue and adjusted EPS of $2.80–$3.00. The stock saw heavy volume after management cited lower COVID sales, patent expiries, and deal dilution as headwinds. U.S. drug-pricing deals and new Medicare pilot programs added pressure.
21 December 2025
····
Shopify Stock (SHOP) News, Price Targets, and 2026 Outlook: Wall Street Upgrades Meet AI Push and Record Holiday Sales

Shopify Stock (SHOP) News, Price Targets, and 2026 Outlook: Wall Street Upgrades Meet AI Push and Record Holiday Sales

Shopify shares closed at $169.57 on Nasdaq Friday, up 1.66%, near multi-month highs and up 59% year-to-date. Analyst price targets rose sharply this week, with Bank of America, DA Davidson, and Wells Fargo all lifting targets. Institutional filings showed Zevenbergen Capital trimmed its stake while AdvisorNet Financial and Meadowbrook Wealth Management increased holdings. Analyst consensus remains split between Buy and Hold.
21 December 2025
···
Booking Holdings (BKNG) Stock News, Forecasts, and Analysis for Dec. 20, 2025: Court Ruling Risk Meets Holiday Travel Tailwinds

Booking Holdings (BKNG) Stock News, Forecasts, and Analysis for Dec. 20, 2025: Court Ruling Risk Meets Holiday Travel Tailwinds

A Berlin court ruled Booking.com and its German subsidiary are liable to compensate 1,099 hotels for damages tied to past “best price” clauses, with damages to be determined later. BKNG last traded near $5,394, up 0.95% for the week, after swings following the ruling. The stock remains about 8.5% below its 52-week high.
21 December 2025
·
Hecla Mining (HL) Stock News, Forecasts and Analysis for Dec. 20, 2025: Silver Record Highs, S&P MidCap 400 Addition, and What Comes Next

Hecla Mining (HL) Stock News, Forecasts and Analysis for Dec. 20, 2025: Silver Record Highs, S&P MidCap 400 Addition, and What Comes Next

Hecla Mining shares closed at $19.67 on Dec. 20, 2025, after hitting a 52-week high of $20.20 amid record silver prices above $65/oz. The stock is set to join the S&P MidCap 400 on Dec. 22, a move expected to boost trading volume. Hecla reported a key permit approval for its 2026 Polaris exploration program in Nevada. Year-to-date, HL has gained nearly 290%.
20 December 2025
··
Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Intuit closed Friday, Dec. 19 at $671.30 after rebounding from early-week losses. The stock remains well below its July 52-week high of $813.70. Intuit announced a multi-year partnership with Circle to integrate USDC stablecoin features into TurboTax, QuickBooks, and Credit Karma. No revenue targets were disclosed.
20 December 2025
··
IBM Stock News and Forecast for 2026: IBM Shares Hold Near $301 as Confluent Deal, Credit Outlook, and Analyst Calls Collide (Dec. 20, 2025)

IBM Stock News and Forecast for 2026: IBM Shares Hold Near $301 as Confluent Deal, Credit Outlook, and Analyst Calls Collide (Dec. 20, 2025)

IBM closed at $300.98 on Dec. 19, 2025, near the top of its 52-week range. The company announced an $11 billion deal to acquire Confluent, drawing scrutiny after S&P Global revised IBM’s outlook to negative over leverage concerns. The EU imposed new regulatory oversight, and analysts issued a downgrade on Dec. 20.
20 December 2025
···
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed shares closed at $174.84 Friday, rebounding 5% after a sharp drop triggered by its Phase 2b BiRCh trial failure in chronic rhinosinusitis without nasal polyps. The company discontinued development for that indication and announced the acquisition of a Phase 2–ready monoclonal antibody, INS1148, to expand its pipeline.
20 December 2025
··
Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook

Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook

Texas Instruments began production at its new Sherman, Texas 300mm wafer fab, part of a planned $40 billion investment. Shares closed at $176.29 on Dec. 19, as investors weighed long-term manufacturing gains against short-term margin concerns. Goldman Sachs downgraded the stock to Sell, citing risks from increased capacity and potential earnings drag.
20 December 2025
··
Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

Salesforce shares closed at $259.91 on Dec. 19, up 0.8%, with about 20.7 million shares traded. The stock remains far below its 52-week high, as investors weigh AI growth prospects against weak SaaS sentiment. Q3 FY2026 revenue rose 9% to $10.3 billion, with Agentforce + Data 360 annual recurring revenue up 114% to $1.4 billion. Salesforce raised its full-year revenue outlook to $41.45–$41.55 billion.
20 December 2025
···
CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave shares jumped 22% to $83 at Friday’s close, partially rebounding from a recent selloff. The move followed news that the company was named as a participant in the U.S. Department of Energy’s Genesis Mission and Citigroup resumed coverage with a Buy rating but lowered its price target.
20 December 2025
··
Lamb Weston (LW) Stock Plunges After Earnings Beat: Margin Pressure, 2026 Outlook, and Analyst Forecasts as of Dec. 20, 2025

Lamb Weston (LW) Stock Plunges After Earnings Beat: Margin Pressure, 2026 Outlook, and Analyst Forecasts as of Dec. 20, 2025

Lamb Weston shares plunged nearly 26% Friday after management warned of continued discounting and higher international costs despite beating Q2 FY2026 earnings expectations. Net sales rose 1% to $1.618 billion, with an 8% volume gain offset by an 8% drop in price/mix. The company said margin pressure may persist into the second half of the year.
20 December 2025
···
Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) shares fell 11.5% to $80.04 on Dec. 20, 2025, after a STAT News report raised doubts about the effectiveness of its lead drug bitopertin and the FDA’s fast-track voucher process. The stock traded between $71.46 and $94.60 on heavy volume after Truist Securities cited the report, fueling concerns about the viability of accelerated approval.
20 December 2025
·
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly shares closed at $1,071.44 on Dec. 19, near record highs, after reporting positive Phase 3 results for its oral weight-loss drug orforglipron. The company also cut prices on Zepbound and Mounjaro in the U.S. and Canada. Lilly’s market value surpassed $1 trillion this year amid growing demand for obesity and cardiometabolic treatments.
20 December 2025
···
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin shares jumped 17.7% to $61.15 Friday after announcing a $4.8 billion all-cash deal to acquire Amicus Therapeutics at $14.50 per share. The acquisition adds two marketed rare-disease drugs and a Phase 3 asset, and resolves U.S. patent litigation over Galafold, delaying generic entry to 2037. BioMarin expects the deal to close in Q2 2026 and be accretive to earnings within a year.
20 December 2025
····
Cisco (CSCO) Stock News, Analyst Forecasts, and 2026 Outlook: What Investors Are Watching on Dec. 20, 2025

Cisco (CSCO) Stock News, Analyst Forecasts, and 2026 Outlook: What Investors Are Watching on Dec. 20, 2025

Cisco shares closed Friday at $78.42, up 1.91%, after heavy trading pushed the stock near its all-time high set during the dot-com era. Morgan Stanley raised its price target to $91 on Dec. 17, citing AI infrastructure demand. Jackson Square Capital increased its stake in Cisco during the third quarter. The company faces scrutiny over a newly disclosed high-severity cybersecurity issue.
20 December 2025
··
CoreWeave Stock (CRWV) Surges on DOE Genesis Mission and Citi Buy Call: News, Forecasts, and 2026 Risks (Dec. 20, 2025)

CoreWeave Stock (CRWV) Surges on DOE Genesis Mission and Citi Buy Call: News, Forecasts, and 2026 Risks (Dec. 20, 2025)

CoreWeave shares surged 22.5% to about $83 in heavy trading after Citigroup resumed coverage with a Buy rating and the U.S. Department of Energy named the company as a Genesis Mission partner. Citi lowered its price target to $135 and flagged “High Risk,” citing strong demand but operational challenges. The stock had dropped 65% from its June high after its March IPO.
20 December 2025
···
National Stock Exchange of India (NSE) Today: Derivatives Reforms, IPO Signals, and Nifty 50 Forecasts as 2026 Approaches

National Stock Exchange of India (NSE) Today: Derivatives Reforms, IPO Signals, and Nifty 50 Forecasts as 2026 Approaches

The National Stock Exchange of India introduced a pre-open session for equity derivatives, aiming to set opening prices through a call auction. On December 20, the Nifty 50 closed at 25,966.40, up 0.58%. The exchange’s listed market capitalization stood at about $5.2 trillion. The long-delayed NSE IPO remains under discussion amid regulatory changes.
20 December 2025
·
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals shares surged 11% on Dec. 17 after JPMorgan upgraded the stock, then retreated to close at $4.26 on Dec. 19 as trading volume spiked. The moves followed positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis, showing a median 43% reduction in polyp burden at 13 weeks. Most adverse events were mild or moderate.
20 December 2025
···
1 … 9 10 11 12 13 … 42

Stock Market Today

  • Power Integrations Announces Inducement Stock Grants for New Executives Under Nasdaq Rule
    June 19, 2026, 6:36 PM EDT. Power Integrations (Nasdaq: POWI) disclosed inducement grants totaling 44,299 restricted and performance stock units to new hires, including General Counsel Andrew Hughes, under Nasdaq Listing Rule 5635(c)(4). The grants comprise 29,408 restricted stock units (RSUs), 2,246 performance stock units (PSUs), and 12,603 long-term performance RSUs (PRSUs) awarded on June 15, 2026. PSUs and PRSUs vest based on company performance metrics for 2026 and 2028, with up to 200% potential payout, subject to continued employment. These inducement awards, approved by the Talent and Compensation Committee, aim to attract key talent amid Power Integrations' focus on power conversion semiconductors for renewable energy sectors.

Latest articles

JBS shutdowns put pressure on U.S. beef as cattle prices rise

JBS shutdowns put pressure on U.S. beef as cattle prices rise

20 June 2026
JBS USA will close its Souderton, PA, and Memphis, TN, meat plants on August 14, cutting 1,693 jobs as tight cattle supplies drive negative U.S. beef margins; USDA data show beef prices up 14.8% year-over-year and forecast to rise another 12.1% in 2026, signaling ongoing cost pressure for packers and consumers.
TSMC Leads Nvidia in Short Week Chip Gains

TSMC Leads Nvidia in Short Week Chip Gains

20 June 2026
TSMC’s U.S.-listed shares soared 6.9% to $462.12, outpacing Nvidia’s 3.0% gain, as investors favored broad chip manufacturing exposure after an interim U.S.-Iran deal eased inflation fears and Taiwan’s central bank raised its 2026 economic-growth forecast to 9.45% on AI-driven semiconductor demand.
Intel Beats AMD for Week After Trump Comments on Apple Chips

Intel Beats AMD for Week After Trump Comments on Apple Chips

20 June 2026
Intel soared 10.6% to a record $133.99 after President Trump said Apple agreed to work with Intel on U.S. chip design and production, though neither company confirmed terms or details; analysts are split on the deal’s value, with Intel’s gains outpacing AMD’s 4.9% rise as the chip sector hit a record close.
Go toTop